Home › Funds › Atom Investors LP › RYTM
Atom Investors LP position in RYTM
RHYTHM PHARMACEUTICALS INC · Health Care
Atom Investors LP reported holding 82,223 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$7.8M, representing 0.54% of its reported portfolio and ranking #20 among its reported holdings. Atom Investors LP has disclosed RYTM holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Atom Investors LP's RYTM position evolved
Atom Investors LP first disclosed a stake in RYTM in Q3 2023 at 19,386 shares (US$444K). The position peaked in Q2 2026 at 73,465 shares, worth US$8.2M. Across 11 filings, Atom Investors LP increased the stake 6 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 82,223 shares valued at US$7.8M — an increase of 8,758 shares quarter over quarter.. Notable position changes include a 66% increase in Q1 2024 (shares fell 5% over the following quarter), a 35% trim in Q2 2024 (shares rose 28% over the following quarter), a 149% increase in Q1 2026 (shares rose 28% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 19.39K | $444.42K | New |
| Q4 2023 | 24.93K | $1.15M | Add |
| Q1 2024 | 41.28K | $1.79M | Add |
| Q2 2024 | 26.63K | $1.09M | Reduce |
| Q4 2024 | 11.61K | $649.65K | New |
| Q1 2025 | 14.96K | $792.54K | Add |
| Q2 2025 | 14.87K | $939.38K | Reduce |
| Q4 2025 | 22.93K | $2.45M | New |
| Q1 2026 | 57.00K | $4.96M | Add |
| Q2 2026 | 73.47K | $8.16M | Add |
| Q3 2026 | 82.22K | $7.83M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RYTM and 13F data
RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RYTM
- RA CAPITAL MANAGEMENT, L.P. 6.67M sh · $740.22M · Q2 2026
- BAKER BROS. ADVISORS LP 5.60M sh · $622.27M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.59M sh · $287.16M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 2.48M sh · $236.20M · Q3 2026
- Checkpoint Capital L.P. 1.22M sh · $115.84M · Q3 2026
- Siren, L.L.C. 1.09M sh · $103.43M · Q3 2026
- Rock Springs Capital Management LP 692.60K sh · $65.95M · Q3 2026
- Sofinnova Investments, Inc. 534.54K sh · $50.90M · Q3 2026
More on Atom Investors LP
FAQ
How long has Atom Investors LP held RYTM?
Atom Investors LP has disclosed RYTM holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
What is Atom Investors LP's current position in RYTM?
As of Q3 2026, Atom Investors LP holds 82.22K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $7.83M, representing 0.54% of its reported portfolio and ranking #20.
Has Atom Investors LP been buying or selling RYTM?
In the latest 13F filing (Q3 2026), Atom Investors LP increased its position in RYTM. The position peaked in Q2 2026 at 73.47K shares.
Which other funds hold RYTM?
Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.